Dynavax Technologies
2100 Powell Street
Suite 300
Emeryville
California
94608
United States
Tel: 510-848-5100
Fax: 510-848-1379
Website: http://www.dynavax.com/
Email: contact@dynavax.com
About Dynavax Technologies
We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.
463 articles about Dynavax Technologies
-
Dynavax Technologies Corporation Completes Symphony Dynamo, Inc. Acquisition
1/4/2010
-
Dynavax Technologies Corporation's European Manufacturing Facility Approved for Commercial Production of HEPLISAV Hepatitis B Surface Antigen
12/9/2009
-
Dynavax Technologies Corporation Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy
11/19/2009
-
Dynavax Technologies Corporation to Acquire Symphony Dynamo, Inc., Including $20 Million in Unrestricted Cash
11/10/2009
-
Dynavax Technologies Corporation Appoints Francis R. Cano, Ph.D. to Board of Directors
11/5/2009
-
Dynavax Technologies Corporation’s HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients
10/30/2009
-
Dynavax Technologies Corporation Announces Third Quarter 2009 Financial Results
10/23/2009
-
Dynavax Technologies Corporation to Report Third Quarter 2009 Financial Results after Market Closes on October 22, 2009
10/22/2009
-
Dynavax Technologies Corporation to Present at the Oppenheimer Healthcare Conference
10/20/2009
-
Dynavax Technologies Corporation Initiates Phase 3 Registration Trial in Chronic Kidney Disease Patients for HEPLISAVTM Hepatitis B Vaccine
9/29/2009
-
Dynavax Technologies Corporation Announces HEPLISAV(TM) Data to Be Presented at IDSA Medical Conference
9/22/2009
-
FDA Gives Dynavax Technologies Corporation OK to Resume Hepatitis B Trials
9/10/2009
-
Dynavax Technologies Corporation Announces Retirement of Chief Financial Officer
8/10/2009
-
Dynavax Technologies Corporation Announces Retirement of Chief Financial Officer
8/10/2009
-
Dynavax Technologies Corporation Announces Second Quarter 2009 Financial Results
8/5/2009
-
Dynavax Technologies Corporation Announces Path for HEPLISAV(TM) Hepatitis B Vaccine Development
8/5/2009
-
Dynavax Technologies Corporation Presents Additional Phase 3 Data for HEPLISAVTM Hepatitis B Vaccine at DDW Medical Conference
6/3/2009
-
Dynavax Technologies Corporation Announces Data Presentations at American Thoracic Society Medical Conference
5/18/2009
-
Dynavax Technologies Corporation Awarded Grant to Support Development of TLR Inhibitors in Skin Diseases
5/13/2009
-
Dynavax Technologies Corporation Announces First Quarter 2009 Financial Results
4/29/2009